Biodesix (BDSX) Equity Average (2019 - 2025)
Biodesix (BDSX) has disclosed Equity Average for 7 consecutive years, with -$2.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 108.59% year-over-year to -$2.1 million, compared with a TTM value of -$2.1 million through Dec 2025, down 108.59%, and an annual FY2025 reading of $9.2 million, down 27.68% over the prior year.
- Equity Average was -$2.1 million for Q4 2025 at Biodesix, down from -$292000.0 in the prior quarter.
- Across five years, Equity Average topped out at $38.8 million in Q1 2021 and bottomed at -$4.2 million in Q3 2023.
- Average Equity Average over 5 years is $12.1 million, with a median of $10.7 million recorded in 2022.
- The sharpest move saw Equity Average crashed 276.99% in 2023, then surged 3563.77% in 2025.
- Year by year, Equity Average stood at $17.9 million in 2021, then crashed by 50.49% to $8.9 million in 2022, then crashed by 82.3% to $1.6 million in 2023, then surged by 1454.98% to $24.4 million in 2024, then tumbled by 108.59% to -$2.1 million in 2025.
- Business Quant data shows Equity Average for BDSX at -$2.1 million in Q4 2025, -$292000.0 in Q3 2025, and $6.1 million in Q2 2025.